[Treatment with Miltex for metastatic skin lesions in breast cancer]  .
Miltex (miltefosine) is a new antiproliferation drug comprising phospholipid ingredients. It is used for topical treatment of metastatic skin lesions in breast cancer. Clinical trials of the drug were conducted in 11 breast cancer patients resistant to standard therapy. Apparent therapeutic effect (partial regression) was registered in 27.3% (3/11). Moderate toxic effects were generally confined to skin itching (36.4%) and scaling (18.2%), erythema (18.2%), and paper skin (45.5%).
Moĭseenko
V M
VM
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Orlova
R V
RV
Ermakova
N A
NA
Protsenko
S A
SA
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000556:secondary; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010767:Phosphorylcholine; C039128:miltefosine
Primenenie Milteksa dlia lecheniia metastaticheskikh porazheniĭ kozhi  pri rake molochnoĭ zhelezy.